Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review.

Yee, Karen S; Alexanderian, David; Feng, Yidie; Ren, Xiaowei; Schweikert, Bernd; Ayodele, Olulade

Yee, Karen S; Alexanderian, David; Feng, Yidie; Ren, Xiaowei; Schweikert, Bernd; Ayodele, Olulade.

Afiliação

Yee KS; Takeda Development Center Americas, Inc., Cambridge, Massachusetts.
Alexanderian D; Takeda Development Center Americas, Inc., Lexington, Massachusetts.
Feng Y; ICON plc, Vancouver, British Columbia, Canada.
Ren X; Takeda Development Center Americas, Inc., Cambridge, Massachusetts.
Schweikert B; ICON plc, Vancouver, British Columbia, Canada.
Ayodele O; Takeda Development Center Americas, Inc., Lexington, Massachusetts.

J Health Econ Outcomes Res ; 9(2): 67-76, 2022.

Article em En | MEDLINE | ID: mdl-36168594

Palavras-chave

Hunter syndrome; MPS II; cognitive impairment; disease burden; enzyme replacement therapy; idursulfase; lysosomal storage disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: J Health Econ Outcomes Res Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google